Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$146.42 USD
+0.45 (0.31%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $146.31 -0.11 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JNJ 146.42 +0.45(0.31%)
Will JNJ be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Other News for JNJ
J&J-backed Rapport Therapeutics prices IPO at $17 per share
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
Halozyme hits 52-week high as patent win prompts guidance raise
Sleep Easy: 3 Safe Stocks That Won’t Have You Stressin’
Goldman cuts 2seventy bio to neutral, cites competition concerns